ICON Public Limited (NASDAQ:ICLR) Given Average Recommendation of “Buy” by Analysts

ICON Public Limited (NASDAQ:ICLR) has been given an average recommendation of “Buy” by the eight brokerages that are currently covering the firm, MarketBeat.com reports. Eight research analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $339.44.

A number of research analysts recently issued reports on the stock. Mizuho restated a “buy” rating and set a $346.00 target price on shares of ICON Public in a research report on Thursday, April 4th. Barclays boosted their target price on shares of ICON Public from $325.00 to $355.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Truist Financial boosted their target price on shares of ICON Public from $357.00 to $367.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. TD Cowen boosted their target price on shares of ICON Public from $343.00 to $349.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Finally, Evercore ISI decreased their price objective on shares of ICON Public from $350.00 to $330.00 and set an “outperform” rating for the company in a research report on Friday, April 26th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ICLR. GAMMA Investing LLC grew its stake in ICON Public by 22.5% during the 1st quarter. GAMMA Investing LLC now owns 174 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 32 shares in the last quarter. Pinnacle Bancorp Inc. grew its stake in ICON Public by 110.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 105 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 55 shares in the last quarter. Steph & Co. grew its stake in ICON Public by 4.6% during the 3rd quarter. Steph & Co. now owns 1,670 shares of the medical research company’s stock valued at $411,000 after acquiring an additional 73 shares in the last quarter. Bruce G. Allen Investments LLC purchased a new stake in ICON Public during the 4th quarter valued at about $25,000. Finally, Riverview Trust Co purchased a new stake in ICON Public during the 1st quarter valued at about $31,000. Institutional investors and hedge funds own 95.61% of the company’s stock.

ICON Public Price Performance

Shares of ICLR opened at $301.61 on Friday. The firm has a market capitalization of $24.88 billion, a PE ratio of 36.45, a price-to-earnings-growth ratio of 1.37 and a beta of 1.15. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.21 and a quick ratio of 1.21. ICON Public has a 1-year low of $181.92 and a 1-year high of $344.77. The company’s fifty day moving average price is $319.48 and its 200-day moving average price is $284.10.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, February 21st. The medical research company reported $3.40 earnings per share for the quarter, beating analysts’ consensus estimates of $3.27 by $0.13. The firm had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.08 billion. ICON Public had a net margin of 8.30% and a return on equity of 11.70%. On average, equities research analysts predict that ICON Public will post 14.4 EPS for the current year.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.